Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-11-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Work Rules" of 广州市香雪制药股份有限公司. It details the committee's composition, responsibilities, decision-making procedures, and operational rules related to the remuneration and assessment of directors and senior management. It references relevant laws and governance codes but does not contain financial statements, earnings data, or shareholder voting results. It is a governance-related document outlining internal rules and committee functions. Therefore, it fits the category of Governance Information (CGR). The document length is 2614 characters, which is consistent with a detailed governance policy document rather than a brief announcement or report publication notice.
2025-11-28 Chinese
董事、高级管理人员引咎辞职和罢免制度
Governance Information Classification · 95% confidence The document is a detailed internal governance policy regarding the resignation and removal procedures for directors and senior management of 广州市香雪制药股份有限公司. It references company bylaws, relevant laws, and stock exchange regulations, focusing on corporate governance structure and management accountability. It does not contain financial data, audit results, or shareholder voting results, nor is it a report or announcement of financial performance. The content aligns with governance practices and internal rules rather than a report or announcement. Therefore, the document fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-11-28 Chinese
董事会秘书工作细则
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作细则' which translates to 'Board Secretary Work Rules' or 'Board Secretary Regulations'. It details the duties, qualifications, appointment, and responsibilities of the company's board secretary. It references relevant laws and regulations governing board secretary roles and company governance. There is no financial data, no report on financial performance, no earnings data, no voting results, no legal proceedings, no capital changes, no merger or acquisition information, and no announcement of a report. The document is a governance-related internal rules document about the board secretary function and governance compliance. Therefore, it fits best under Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RPA or RNS. Hence, the classification is CGR with high confidence.
2025-11-28 Chinese
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board Audit Committee Working Rules" of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the structure, responsibilities, and procedures of the audit committee under the board of directors. The content focuses on governance, internal controls, audit oversight, and committee operations rather than financial results or reports. It does not contain financial statements or audit opinions but rather governance rules related to audit functions. This fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document length is under 5,000 characters, but it is a substantive governance document, not a mere announcement. Therefore, the appropriate classification is CGR with high confidence.
2025-11-28 Chinese
独立董事专门会议工作细则
Governance Information Classification · 95% confidence The document is titled as rules for the independent directors' special meetings of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details governance mechanisms, meeting procedures, duties, and responsibilities of independent directors. It references company law, securities law, and stock exchange listing rules, focusing on internal governance and board procedures. There is no financial data, no report of financial results, no announcement of voting results, no mention of dividends, no legal proceedings, no capital changes, no earnings or annual report content. The document is a governance-related internal regulation or guideline. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report but a substantive governance document.
2025-11-28 Chinese
第九届监事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 23rd meeting of the 9th Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes decisions on revising the company's articles of association, abolishing the supervisory board, and renewing the appointment of an accounting firm. The document is an official meeting resolution announcement rather than a full report or detailed financial statement. It does not contain financial data or detailed audit results but rather governance and management decisions requiring shareholder approval. The document length is short (1322 characters), and it serves as a formal disclosure of board/management decisions. Therefore, it fits best under Board/Management Information (MANG).
2025-11-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.